Autoimmune Diseases

Immunology
6
Pipeline Programs
8
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
150%
Cell Therapy
150%
+ 6 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Design Therapeutics
1 program
1
Autologous mesenchymal stem cells from adipose tissue.Phase 1/21 trial
Active Trials
NCT01056471CompletedEst. Jun 2015
Precision BioSciences
1 program
1
CD19 CAR-T cellsPhase 1/2Cell Therapy1 trial
Active Trials
NCT07161193Not Yet Recruiting30Est. Nov 2027
Connect Biopharma
Connect BiopharmaSAN DIEGO, CA
2 programs
2
CBP-307Phase 11 trial
CBP-307Phase 11 trial
Active Trials
NCT02280434CompletedEst. Aug 2015
NCT04818229CompletedEst. Mar 2022
Bristol Myers Squibb
1 program
1
BMS-986165Phase 11 trial
Active Trials
NCT03956953Completed135Est. Sep 2019
Seismic Therapeutic
Seismic TherapeuticMA - Watertown
1 program
1
S-4321Phase 11 trial
Active Trials
NCT07455578Not Yet RecruitingEst. Jun 2027
Octapharma
OctapharmaAustria - Vienna
1 program
GammanormN/A1 trial
Active Trials
NCT03656640Terminated60Est. Dec 2019
Grifols
GrifolsNEW YORK, NY
1 program
Study of Infections in Patients With Autoimmune Diseases Treated With RituximabN/AMonoclonal Antibody1 trial
Active Trials
NCT03778840CompletedEst. May 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Precision BioSciencesCD19 CAR-T cells
Design TherapeuticsAutologous mesenchymal stem cells from adipose tissue.
Seismic TherapeuticS-4321
Connect BiopharmaCBP-307
Bristol Myers SquibbBMS-986165
Connect BiopharmaCBP-307
GrifolsStudy of Infections in Patients With Autoimmune Diseases Treated With Rituximab
OctapharmaGammanorm

Clinical Trials (8)

Total enrollment: 225 patients across 8 trials

NCT07161193Precision BioSciencesCD19 CAR-T cells

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

Start: Sep 2025Est. completion: Nov 202730 patients
Phase 1/2Not Yet Recruiting
NCT01056471Design TherapeuticsAutologous mesenchymal stem cells from adipose tissue.

Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis

Start: Jan 2010Est. completion: Jun 2015
Phase 1/2Completed
NCT07455578Seismic TherapeuticS-4321

Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease

Start: Feb 2026Est. completion: Jun 2027
Phase 1Not Yet Recruiting
NCT04818229Connect BiopharmaCBP-307

A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects

Start: Jun 2021Est. completion: Mar 2022
Phase 1Completed
NCT03956953Bristol Myers SquibbBMS-986165

Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects

Start: Apr 2019Est. completion: Sep 2019135 patients
Phase 1Completed
NCT02280434Connect BiopharmaCBP-307

Phase 1 Study Accessing the Safety and Tolerability of CBP-307

Start: Nov 2014Est. completion: Aug 2015
Phase 1Completed
NCT03778840GrifolsStudy of Infections in Patients With Autoimmune Diseases Treated With Rituximab

Study of Infections in Patients With Autoimmune Diseases Treated With Rituximab

Start: May 2019Est. completion: May 2022
N/ACompleted
NCT03656640OctapharmaGammanorm

Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases

Start: Nov 2016Est. completion: Dec 201960 patients
N/ATerminated

Related Jobs in Immunology

Regulatory Affairs Manager(Immunology), Korea

AbbVie
Seoul, Seoul
6h ago

Regional Sales Trainer - Rheumatology (Mid Atlantic/Central)

AbbVie
Remote
7h ago

Product Specialist - Immunology

Johnson & Johnson
Kibbutz Shefayim, Center District, Israel
20h ago

Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine

Johnson & Johnson
Detroit, Michigan, United States
20h ago

Senior Medical Science Liaison, Dermatology - Indianapolis

Johnson & Johnson
Indianapolis, Indiana, United States
20h ago
$137K - $236K/yr

Field Reimbursement Manager - Rheumatology - Seattle, WA (North)

Johnson & Johnson
Seattle, Washington, United States of America
20h ago
$100K - $175K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

8 companies competing in this space

Related Indications

Rheumatoid Arthritis(475)Psoriasis(206)Ulcerative Colitis(151)Atopic Dermatitis(144)Crohn's Disease(140)Systemic Lupus Erythematosus(85)Arthritis, Rheumatoid(61)Plaque Psoriasis(53)Crohn Disease(49)Ankylosing Spondylitis(33)